Corcept Therapeutics Incorporated

Equities

CORT

US2183521028

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
25.19 USD -0.51% Intraday chart for Corcept Therapeutics Incorporated +1.78% -22.44%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Corcept Therapeutics Insider Sold Shares Worth $430,475, According to a Recent SEC Filing MT
Sector Update: Health Care Stocks Advance Friday Afternoon MT
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating MT
Sector Update: Health Care Stocks Gain Pre-Bell Friday MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance; Shares Gain Pre-Bell MT
Sector Update: Health Care MT
Corcept Therapeutics Q4 Net Income, Revenue Increase; Reiterates Guidance MT
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024 CI
Transcript : Corcept Therapeutics Incorporated, Q4 2023 Earnings Call, Feb 15, 2024
Corcept Therapeutics Incorporated Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Corcept Therapeutics Incorporated Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Corcept Therapeutics Incorporated Announces Preliminary Results from Prevalence Phase of CATALYST Clinical Trial CI
Corcept Therapeutics Incorporated Appoints Roberto Vieira as President, Oncology CI
Corcept Therapeutics Sees 31% Increase in Q4 Revenue, Issues 2024 Revenue Guidance MT
Corcept Therapeutics Incorporated announces an Equity Buyback for $200 million worth of its shares. CI
Corcept Therapeutics Incorporated Provides Revenue Guidance for the Year 2024 CI
Corcept Therapeutics Incorporated authorizes a Buyback Plan. CI
HC Wainwright Adjusts Corcept Therapeutics' Price Target to $28 From $34, Keeps Buy Rating MT
Top Midday Decliners MT
Wall Street Set to Open 2024 Lower Amid Rise in Oil Prices, Ahead of Manufacturing, Construction Data MT
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday MT
Sector Update: Health Care MT
Corcept Therapeutics' Patents Not Infringed by Teva Pharmaceuticals, US Court Says MT
Corcept Therapeutics Shares Slide Premarket on Loss in Teva Patent Suit DJ
US Equity Futures Set Kick Off 2024 Lower Ahead of Manufacturing PMI, Construction Data MT
Chart Corcept Therapeutics Incorporated
More charts
Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
25.19 USD
Average target price
42.8 USD
Spread / Average Target
+69.91%
Consensus